Renovus-Backed BlueRidge Life Sciences Formed by Uniting Suttons Creek, Modality Solutions, CLINTREX and ToxStrategies

BlueRidge Life Sciences (Renovus-backed) Acquires Design Science

January 23, 2026

Healthcare Services

BlueRidge Life Sciences, a Renovus Capital Partners portfolio company, has acquired Design Science, a human factors and usability engineering consultancy serving medical device, pharmaceutical, and biotechnology clients. The deal expands BlueRidge's human factors, usability testing, and use-related risk analysis capabilities and will let Design Science continue operating under its existing brand with current leadership.

ToxStrategies Acquires Suttons Creek

August 13, 2024

Healthcare Services

ToxStrategies, a Renovus Capital Partners portfolio company, has acquired Suttons Creek to expand its combination-product development and regulatory consulting capabilities. Brookside Capital Partners provided financing to support the add-on acquisition; Suttons Creek will operate as a division of ToxStrategies and its founder Steven Badelt will continue to lead the business. Terms were not disclosed.

ToxStrategies (Renovus-backed) Acquires Modality Solutions

August 8, 2023

Healthcare Services

ToxStrategies, a Renovus Capital Partners-backed life sciences consulting platform, has acquired Modality Solutions, a Houston-based firm specializing in biopharmaceutical cold-chain optimization and shipping validation testing. The add-on expands ToxStrategies' cold-chain, package engineering, and regulatory testing capabilities and will operate as a division of ToxStrategies with Modality's founders continuing to lead the business.

ToxStrategies Acquires Clintrex Research Corporation

June 25, 2024

Healthcare Services

ToxStrategies, a Renovus Capital Partners–backed scientific consulting firm based in Katy, Texas, has acquired Clintrex Research Corporation, a Sarasota-based clinical and regulatory development services provider focused on neurodegenerative and CNS therapies. The deal (terms undisclosed) expands ToxStrategies' clinical, regulatory, biostatistics and drug‑development capabilities and is intended to broaden its end‑market reach in the life sciences sector.

Renovus Capital Partners Forms Life Sciences Commercialization Platform by Merging MC3 and Curtis Learning

July 13, 2022

Healthcare Services

Renovus Capital Partners has created a new life sciences commercialization platform through a majority investment and merger of MC3 and Curtis Learning. The combined company brings together MC3's meeting production and virtual delivery technology with Curtis Learning's scientific training expertise to scale services for pharmaceutical and biotech clients.

Renovus Capital Partners Majority Investment in ToxStrategies

January 24, 2023

Healthcare Services

Renovus Capital Partners made a majority investment in ToxStrategies, a multidisciplinary scientific consulting firm specializing in toxicology, epidemiology, exposure sciences and regulatory compliance. Five Points Capital provided debt and equity co-investment to support the transaction; terms were not disclosed and the deal was described as a recapitalization to support growth and expand services, staff and geographic reach.